Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04991948 · ClinicalTrials.gov registry record · Phase 1
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
A Phase 1 study of Unresectable Metastatic Colorectal Cancer, sponsored by Celyad Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 5
- Study locations
NCT04991948 is a Phase 1 study of Unresectable Metastatic Colorectal Cancer that is actively recruiting participants, run by Celyad Oncology. The registered enrollment target is 34 participants, below the 140-participant average among 3 other Unresectable Metastatic Colorectal Cancer trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT04991948, a Phase 1 study of Unresectable Metastatic Colorectal Cancer, is actively recruiting participants, sponsored by Celyad Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG CYAD-101
- DRUG FOLFOX
Study Locations (5)
Other
- UZ Antwerpen - Edegem
- UZ Gent - Ghent
- UZ Leuven - Leuven
Florida
- Mayo Clinic - Jacksonville
- Moffit Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-11-22 |
| Est. Completion | 2038-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04991948
The ClinicalTrials.gov registry entry for NCT04991948 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 3 other Unresectable Metastatic Colorectal Cancer trials with a reported enrollment target (76% lower). The listed sponsor is Celyad Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unresectable Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04991948 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Other, Florida.
Frequently Asked Questions
What is clinical trial NCT04991948 about?
NCT04991948 is a clinical study titled "Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer". The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment.
What is the current status of trial NCT04991948?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2021-11-22. Estimated completion is 2038-05-25.
What conditions does trial NCT04991948 study?
This clinical trial studies the following conditions: Unresectable Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT04991948?
The interventions under investigation include: Pembrolizumab (DRUG), CYAD-101 (DRUG), FOLFOX (DRUG).
Who is sponsoring clinical trial NCT04991948?
This trial is sponsored by Celyad Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04991948 being conducted?
This trial has 5 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
RECRUITING · Phase 1
-
First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.